A small band of patients and a scientist tried to free their existing genetic testing data for cancer research. It was harder than they expected.
Feeds
17068 items (17068 unread) in 74 feeds
Acinar Cell Carcinoma
(162 unread)
Acinic Cell Carcinoma
(76 unread)
Adenoid Cystic Carcinoma
(317 unread)
Adrenal Gland Cancer
(1406 unread)
Ampulla Of Vater
(195 unread)
Anal Cancer
(1586 unread)
Angiosarcoma
(445 unread)
Appendix Cancer
(359 unread)
Bile Duct Cancer
(2019 unread)
Brain and CNS
(2434 unread)
Carcinoid
(543 unread)
Endocrine/Neuroendocrine
(1900 unread)
Gall Bladder Cancer
(599 unread)
Hemangioendothelioma
(190 unread)
Hepatoblastoma
(341 unread)
Pancreas
(287 unread)
Phyllodes
(202 unread)
PMP and Mucinous Tumors
(198 unread)
Rhabdomyosarcoma
(633 unread)
Sarcoma
(3176 unread)
Google - Angiosarcoma (100 unread)
-
Data Pirates: Patients And Scientist Battle To Liberate Genetic Testing Results - Forbes
Posted: January 17th, 2019, 12:00pm GMT
Data Pirates: Patients And Scientist Battle To Liberate Genetic Testing Results Forbes -
TRACON Pharmaceuticals (TCON) vs. BioCardia (BCDA) Head-To-Head Analysis - Modern Readers
Posted: January 17th, 2019, 11:42am GMT
TRACON Pharmaceuticals (TCON) vs. BioCardia (BCDA) Head-To-Head Analysis Modern ReadersBioCardia (OTCMKTS:BCDA) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the better business?
-
Guest opinion: Animal research can save people and their pets from cancer - Deseret News
Posted: January 17th, 2019, 1:00am GMT
Guest opinion: Animal research can save people and their pets from cancer Deseret NewsIn October, James P. Allison, a researcher at the MD Anderson Cancer Center in Houston, and Tasuku Honjo, a scientist at Kyoto University in Japan, won the ...
-
TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer Purchases 49,000 Shares - Modern Readers
Posted: January 16th, 2019, 10:40pm GMT
TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer Purchases 49,000 Shares Modern ReadersTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer acquired 49000 shares of TRACON Pharmaceuticals stock in a transaction on Friday, ...
-
Head to Head Survey: BioCardia (BCDA) vs. TRACON Pharmaceuticals (TCON) - Baseball Daily News
Posted: January 15th, 2019, 9:52am GMT
Head to Head Survey: BioCardia (BCDA) vs. TRACON Pharmaceuticals (TCON) Baseball Daily NewsBioCardia (OTCMKTS:BCDA) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the superior business?
-
TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Buys $32,340.00 in Stock - PressOracle
Posted: January 15th, 2019, 11:31pm GMT
TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Buys $32,340.00 in Stock PressOracleTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer purchased 49000 shares of the stock in a transaction that occurred on Friday, December ...
-
$0.99 EPS Expected for Middlefield Banc Corp. (MBCN); Athenex (ATNX) Shorts Lowered By 3.81% – The Financial Examiner - The FinExaminer
Posted: January 14th, 2019, 8:51am GMT
$0.99 EPS Expected for Middlefield Banc Corp. (MBCN); Athenex (ATNX) Shorts Lowered By 3.81% – The Financial Examiner The FinExaminerAnalysts expect Middlefield Banc Corp. (NASDAQ:MBCN) to report $0.99 EPS on January, 23.They anticipate $0.34 EPS change or 52.31% from last quarter's ...
-
TRACON Pharmaceuticals Inc (TCON) CEO Purchases $32,340.00 in Stock - Fairfield Current
Posted: January 14th, 2019, 4:06am GMT
TRACON Pharmaceuticals Inc (TCON) CEO Purchases $32,340.00 in Stock Fairfield CurrentTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer bought 49000 shares of the business's stock in a transaction that occurred on Friday, ...
-
TRACON Pharmaceuticals (NASDAQ:TCON) Given New $9.00 Price Target at BTIG Research - Fairfield Current
Posted: January 13th, 2019, 3:39am GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Given New $9.00 Price Target at BTIG Research Fairfield CurrentTRACON Pharmaceuticals (NASDAQ:TCON) had its target price reduced by BTIG Research to $9.00 in a research note issued on Wednesday, December 26th, ...
-
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Sellers Declined By 6.73% Their Shorts As Of Jan 12, 2019 - Z Tribune
Posted: January 12th, 2019, 10:22am GMT
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Sellers Declined By 6.73% Their Shorts As Of Jan 12, 2019 Z TribuneChange of 6.73% for Tracon Pharmaceuticals Inc (NASDAQ:TCON)'s shares shorted was recorded. In January was issued TCON's total 134400 shares shorted ...
-
Head to Head Contrast: TRACON Pharmaceuticals (TCON) against BioCardia (BCDA) - BharataPress
Posted: January 11th, 2019, 7:44am GMT
Head to Head Contrast: TRACON Pharmaceuticals (TCON) against BioCardia (BCDA) BharataPressTRACON Pharmaceuticals (NASDAQ:TCON) and BioCardia (OTCMKTS:BCDA) are both small-cap medical companies, but which is the better stock? We will ...
-
Comparing BioCardia (BCDA) and TRACON Pharmaceuticals (TCON) - Modern Readers
Posted: January 10th, 2019, 11:22am GMT
Comparing BioCardia (BCDA) and TRACON Pharmaceuticals (TCON) Modern ReadersBioCardia (OTCMKTS:BCDA) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the better business?
-
Ken Pribil Jr. Foundation Supports Angiosarcoma Research at Memorial Sloan Kettering Cancer Center - PR Web
Posted: January 9th, 2019, 1:11pm GMT
Ken Pribil Jr. Foundation Supports Angiosarcoma Research at Memorial Sloan Kettering Cancer Center PR WebTo fulfill its mission of supporting sarcoma cancer research, the Ken Pribil Jr. Foundation recently made its fifth annual Sarcoma Research Grant to Memorial ...
-
TRACON Pharmaceuticals (TCON) Stock Rating Upgraded by Zacks Investment Research - XNewsPress
Posted: January 9th, 2019, 9:20am GMT
TRACON Pharmaceuticals (TCON) Stock Rating Upgraded by Zacks Investment Research XNewsPressZacks Investment Research upgraded shares of TRACON Pharmaceuticals (NASDAQ:TCON) from a sell rating to a hold rating in a research report report ...
-
TRACON Pharmaceuticals (TCON) Lifted to “Hold” at Zacks Investment Research - Fairfield Current
Posted: January 8th, 2019, 9:30am GMT
TRACON Pharmaceuticals (TCON) Lifted to “Hold” at Zacks Investment Research Fairfield CurrentZacks Investment Research upgraded shares of TRACON Pharmaceuticals (NASDAQ:TCON) from a sell rating to a hold rating in a research report sent to ...
-
$-0.14 EPS Expected for Yatra Online, Inc. (YTRA); Athenex (ATNX) Shorts Lowered By 3.81% – The Financial Examiner - The FinExaminer
Posted: January 7th, 2019, 10:03am GMT
$-0.14 EPS Expected for Yatra Online, Inc. (YTRA); Athenex (ATNX) Shorts Lowered By 3.81% – The Financial Examiner The FinExaminerAthenex Inc (NASDAQ:ATNX) had a decrease of 3.81% in short interest. ATNX's SI was 4.08 million shares in January as released by FINRA. Its down 3.81% ...
-
Charles Theuer Buys 49,000 Shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock - PressOracle
Posted: January 7th, 2019, 5:33am GMT
Charles Theuer Buys 49,000 Shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock PressOracleTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer purchased 49000 shares of the stock in a transaction dated Friday, December 21st.
-
Insider Purchaseing: TRACON Pharmaceuticals Inc (TCON) CEO Purchased 49000 Shares of Shares - BharataPress
Posted: January 7th, 2019, 3:52am GMT
Insider Purchaseing: TRACON Pharmaceuticals Inc (TCON) CEO Purchased 49000 Shares of Shares BharataPressTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer purchased 49,000 shares of the firm's stock in a transaction on Friday, December 21st.
-
Charles Theuer Acquires 49,000 Shares of TRACON Pharmaceuticals Inc (TCON) Stock - Fairfield Current
Posted: January 6th, 2019, 10:05am GMT
Charles Theuer Acquires 49,000 Shares of TRACON Pharmaceuticals Inc (TCON) Stock Fairfield CurrentTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer bought 49000 shares of the company's stock in a transaction that occurred on Friday, ...
-
Trellus Management Company Has Cut Its Pacific Biosciences Calif In (PACB) Holding; Tracon Pharmaceuticals (TCON) Shorts Down By 6.73% - The FinExaminer
Posted: January 5th, 2019, 4:12pm GMT
Trellus Management Company Has Cut Its Pacific Biosciences Calif In (PACB) Holding; Tracon Pharmaceuticals (TCON) Shorts Down By 6.73% The FinExaminerTrellus Management Company Llc decreased Pacific Biosciences Calif In (PACB) stake by 24.51% reported in 2018Q3 SEC filing. Trellus Management ...
-
TRACON Pharmaceuticals (NASDAQ:TCON) Given New $9.00 Price Target at BTIG Research - Fairfield Current
Posted: January 5th, 2019, 9:35am GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Given New $9.00 Price Target at BTIG Research Fairfield CurrentTRACON Pharmaceuticals (NASDAQ:TCON) had its target price lowered by equities researchers at BTIG Research to $9.00 in a research report issued to ...
-
Orphan Drugs Market Growth and Industry Revenue By Top Key Players "AbbVie Inc., Aegerion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation And Many Others" - openPR
Posted: January 4th, 2019, 6:00pm GMT
Orphan Drugs Market Growth and Industry Revenue By Top Key Players "AbbVie Inc., Aegerion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation And Many Others" openPRGlobal Orphan Drugs Market is expected to garner $169 billion from $106 billion and register a CAGR of 6.8% during the forecast period, 2016-2022. Orphan ...
-
TRACON Pharmaceuticals (TCON) Price Target Lowered to $9.00 at BTIG Research - Modern Readers
Posted: January 4th, 2019, 9:34am GMT
TRACON Pharmaceuticals (TCON) Price Target Lowered to $9.00 at BTIG Research Modern ReadersTRACON Pharmaceuticals (NASDAQ:TCON) had its price objective lowered by analysts at BTIG Research to $9.00 in a research report issued to clients and ...
-
Head to Head Contrast: TRACON Pharmaceuticals (TCON) versus BioCardia (BCDA) - PressOracle
Posted: January 4th, 2019, 10:21pm GMT
Head to Head Contrast: TRACON Pharmaceuticals (TCON) versus BioCardia (BCDA) PressOracleTRACON Pharmaceuticals (NASDAQ:TCON) and BioCardia (OTCMKTS:BCDA) are both small-cap medical companies, but which is the better stock? We will ...
-
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Can't Be Less Risky. Short Interest Decreased - MoneyMakingArticles
Posted: January 3rd, 2019, 4:38pm GMT
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Can't Be Less Risky. Short Interest Decreased MoneyMakingArticlesThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered a decrease of 6.73% in short interest. TCON's total short interest was 134400 shares in.
-
Is Tracon Pharmaceuticals Inc (NASDAQ:TCON)'s Fuel Running High? Reports Show Less Sellers - Thorold News
Posted: January 3rd, 2019, 4:32pm GMT
Is Tracon Pharmaceuticals Inc (NASDAQ:TCON)'s Fuel Running High? Reports Show Less Sellers Thorold NewsThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered a decrease of 6.73% in short interest. TCON's total short interest was 134400 shares in.
-
BTIG Research Cuts TRACON Pharmaceuticals (TCON) Price Target to $9.00 - PressOracle
Posted: January 3rd, 2019, 9:15am GMT
BTIG Research Cuts TRACON Pharmaceuticals (TCON) Price Target to $9.00 PressOracleTRACON Pharmaceuticals (NASDAQ:TCON) had its price objective dropped by stock analysts at BTIG Research to $9.00 in a note issued to investors on ...
-
TRACON Pharmaceuticals Inc (TCON) Shares Bought by Bridgeway Capital Management Inc. - Fairfield Current
Posted: January 3rd, 2019, 2:34am GMT
TRACON Pharmaceuticals Inc (TCON) Shares Bought by Bridgeway Capital Management Inc. Fairfield CurrentBridgeway Capital Management Inc. lifted its stake in shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) by 100.0% in the 3rd quarter, according to the ...
-
TRACON Pharmaceuticals (TCON) Shares Price Down 8.1% - BharataPress
Posted: January 2nd, 2019, 9:00pm GMT
TRACON Pharmaceuticals (TCON) Shares Price Down 8.1% BharataPressShares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) were down 8.1% during trading on Monday . The company traded as low as $0.59 and last traded at ...
-
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - P&T Community
Posted: January 2nd, 2019, 7:42pm GMT
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) P&T CommunityEMERYVILLE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of ...
-
Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference - P&T Community
Posted: January 2nd, 2019, 7:42pm GMT
Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference P&T CommunityWESTLAKE VILLAGE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C.
-
Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019 - P&T Community
Posted: January 2nd, 2019, 7:42pm GMT
Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019 P&T CommunityBOSTON and LONDON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical ...
-
OrthoPediatrics Corp. Files Sanctions Motion Against a Former Employee and WishBone Medical, Inc. - P&T Community
Posted: January 2nd, 2019, 7:42pm GMT
OrthoPediatrics Corp. Files Sanctions Motion Against a Former Employee and WishBone Medical, Inc. P&T CommunityWARSAW, Indiana, Jan. 02, 2019 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on ...
-
Venom Can Be Used As Future Therapeutic Agents Against Cancer, TB, And HIV/AIDS - Science Trends
Posted: January 2nd, 2019, 5:52pm GMT
Venom Can Be Used As Future Therapeutic Agents Against Cancer, TB, And HIV/AIDS Science TrendsVenom is a secretion produced by specific animals, which is synthesized in the specialized cells of their body. Animal venoms constitute a plethora of.
-
Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy - P&T Community
Posted: January 2nd, 2019, 11:41am GMT
Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy P&T Community... -- Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin ...
-
BTIG Research Cuts TRACON Pharmaceuticals (TCON) Price Target to $9.00 - Baseball Daily News
Posted: January 2nd, 2019, 10:18am GMT
BTIG Research Cuts TRACON Pharmaceuticals (TCON) Price Target to $9.00 Baseball Daily NewsTRACON Pharmaceuticals (NASDAQ:TCON) had its price target lowered by BTIG Research to $9.00 in a report issued on Wednesday, December 26th, The Fly ...
-
TRACON Pharmaceuticals (TCON) Stock Price Down 8.1% - Fairfield Current
Posted: January 2nd, 2019, 9:34am GMT
TRACON Pharmaceuticals (TCON) Stock Price Down 8.1% Fairfield CurrentTRACON Pharmaceuticals Inc (NASDAQ:TCON)'s share price was down 8.1% during mid-day trading on Monday . The stock traded as low as $0.59 and last ...
-
TRACON Pharmaceuticals (TCON) Shares Down 8.1% - BharataPress
Posted: January 1st, 2019, 9:24am GMT
TRACON Pharmaceuticals (TCON) Shares Down 8.1% BharataPressTRACON Pharmaceuticals Inc (NASDAQ:TCON) dropped 8.1% on Monday . The stock traded as low as $0.59 and last traded at $0.57. Approximately 4,710 ...
-
Insider Buying: TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Purchases 49,000 Shares of Stock - Modern Readers
Posted: December 31st, 2018, 10:48am GMT
Insider Buying: TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Purchases 49,000 Shares of Stock Modern ReadersTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer purchased 49000 shares of TRACON Pharmaceuticals stock in a transaction that ...
-
BTIG Research Trims TRACON Pharmaceuticals (TCON) Target Price to $9.00 - BharataPress
Posted: December 30th, 2018, 6:12pm GMT
BTIG Research Trims TRACON Pharmaceuticals (TCON) Target Price to $9.00 BharataPressTRACON Pharmaceuticals (NASDAQ:TCON) had its target price trimmed by BTIG Research to $9.00 in a research note released on Wednesday morning, The ...
-
Angiosarcomas Treatment Market Benefit and Volume 2018 with Status and Prospect to 2026 - Coherent Chronicle
Posted: December 30th, 2018, 1:14pm GMT
Angiosarcomas Treatment Market Benefit and Volume 2018 with Status and Prospect to 2026 Coherent ChronicleAngiosarcomas Treatment Market report is a research database spread across various pages with multiple tables and figures in it. The research covers a ...
-
Insider Buying: TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Acquires 49,000 Shares of Stock - PressOracle
Posted: December 30th, 2018, 11:56am GMT
Insider Buying: TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Acquires 49,000 Shares of Stock PressOracleTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer bought 49000 shares of the company's stock in a transaction on Friday, December 21st.
-
TRACON Pharmaceuticals (TCON) Sees Unusually-High Trading Volume - BharataPress
Posted: December 30th, 2018, 7:28am GMT
TRACON Pharmaceuticals (TCON) Sees Unusually-High Trading Volume BharataPressShares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) saw unusually-high trading volume on Thursday . Approximately 2,445,910 shares changed hands ...
-
TRACON Pharmaceuticals (TCON) Sees Unusually-High Trading Volume - Fairfield Current
Posted: December 29th, 2018, 2:37pm GMT
TRACON Pharmaceuticals (TCON) Sees Unusually-High Trading Volume Fairfield CurrentShares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) saw unusually-high trading volume on Thursday . Approximately 2445910 shares changed hands ...
-
EPS for Brandywine Realty Trust (BDN) Expected At $0.35; Tracon Pharmaceuticals (TCON) SI Decreased By 6.73% - D Minute
Posted: December 29th, 2018, 10:01am GMT
EPS for Brandywine Realty Trust (BDN) Expected At $0.35; Tracon Pharmaceuticals (TCON) SI Decreased By 6.73% D MinuteAnalysts expect Brandywine Realty Trust (NYSE:BDN) to report $0.35 EPS on January, 24.They anticipate $0.03 EPS change or 9.37% from last quarter's $0.32 ...
-
BTIG Research Trims TRACON Pharmaceuticals (TCON) Target Price to $9.00 - Fairfield Current
Posted: December 29th, 2018, 9:33am GMT
BTIG Research Trims TRACON Pharmaceuticals (TCON) Target Price to $9.00 Fairfield CurrentTRACON Pharmaceuticals (NASDAQ:TCON) had its target price cut by BTIG Research to $9.00 in a research note issued to investors on Wednesday morning, ...
-
Angiosarcomas Treatment Market Benefit and Volume 2018 with Status and Prospect to 2026 - Coherent Wire
Posted: December 28th, 2018, 11:54am GMT
Angiosarcomas Treatment Market Benefit and Volume 2018 with Status and Prospect to 2026 Coherent WireAngiosarcomas Treatment Market Research report contains a qualified and in-depth examination of industry which provides overview of Product Specification, ...
-
TRACON Pharmaceuticals (TCON) Sees Strong Trading Volume - Modern Readers
Posted: December 28th, 2018, 11:46am GMT
TRACON Pharmaceuticals (TCON) Sees Strong Trading Volume Modern ReadersTRACON Pharmaceuticals Inc (NASDAQ:TCON) saw an uptick in trading volume on Thursday . 2445910 shares were traded during mid-day trading, ...
-
Gala Pharmaceutical Receives Temporary State License for Cannabis Testing - P&T Community
Posted: December 28th, 2018, 11:12am GMT
Gala Pharmaceutical Receives Temporary State License for Cannabis Testing P&T CommunityIRVINE, Calif., Dec. 28, 2018 (GLOBE NEWSWIRE) -- Gala Pharmaceutical California Inc., a subsidiary of Gala Pharmaceutical, Inc. (Ticker: GLPH), today ...
-
BELLUS Health Announces Payment of $134149 to Thallion CVR Holders - P&T Community
Posted: December 28th, 2018, 10:12am GMT
BELLUS Health Announces Payment of $134149 to Thallion CVR Holders P&T CommunityLAVAL, Quebec, Dec. 28, 2018 (GLOBE NEWSWIRE) -- BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage ...
-
TRACON Pharmaceuticals (TCON) PT Lowered to $9.00 - Modern Readers
Posted: December 28th, 2018, 9:33am GMT
TRACON Pharmaceuticals (TCON) PT Lowered to $9.00 Modern ReadersTRACON Pharmaceuticals (NASDAQ:TCON) had its price objective decreased by investment analysts at BTIG Research to $9.00 in a research note issued on ...
-
Mesoblast Corporate Review - P&T Community
Posted: December 28th, 2018, 9:12am GMT
Mesoblast Corporate Review P&T CommunityNEW YORK and MELBOURNE, Australia, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast will enter 2019 with the most mature cell therapy product pipeline ...
-
Doug Disraeli D.D.S. Offers Tips on How to Stick to Your Daily Flossing Resolutions - P&T Community
Posted: December 28th, 2018, 9:12am GMT
Doug Disraeli D.D.S. Offers Tips on How to Stick to Your Daily Flossing Resolutions P&T CommunitySAN DIEGO, Dec. 28, 2018 (GLOBE NEWSWIRE) -- With the holiday season among us, Dr. Doug Disraeli knows how hard it can be sticking to a healthy dental ...
-
Terveystalo has completed the acquisition of Finnish healthcare operations of Attendo - P&T Community
Posted: December 28th, 2018, 8:12am GMT
Terveystalo has completed the acquisition of Finnish healthcare operations of Attendo P&T CommunityTerveystalo Plc Stock exchange release 28 December 2018 at 11:30 a.m. EET. Terveystalo has completed the acquisition of Attendo's Finnish Health Services ...
-
Dr. Samuel Hahn Opens Plastic Surgery Center in Baltimore - P&T Community
Posted: December 27th, 2018, 9:01pm GMT
Dr. Samuel Hahn Opens Plastic Surgery Center in Baltimore P&T CommunityBALTIMORE, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Maryland Center for Facial Plastic Surgery, led by Samuel Hahn, MD, offers the full scope of facial plastic ...
-
iCAD Announces CFO Transition - P&T Community
Posted: December 27th, 2018, 8:01pm GMT
iCAD Announces CFO Transition P&T CommunityNASHUA, N.H., Dec. 27, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology company providing innovative cancer detection ...
-
Tauriga Sciences Inc. Selects Name & Logo Under Which it will Brand its Cannabis Infused Chewing Gum Product Line - P&T Community
Posted: December 27th, 2018, 7:00pm GMT
Tauriga Sciences Inc. Selects Name & Logo Under Which it will Brand its Cannabis Infused Chewing Gum Product Line P&T CommunityNew York, NY, Dec. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), engaged in building ...
-
Rheumatology Community Urges CMS to Proceed with Caution When Considering IPI Drug Pricing Model - P&T Community
Posted: December 27th, 2018, 6:00pm GMT
Rheumatology Community Urges CMS to Proceed with Caution When Considering IPI Drug Pricing Model P&T CommunityACR Recommends CMS Make Drug Pricing Demonstration Voluntary; Better Address Financial and Administrative Challenges for Providers to Protect Patient ...
-
Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook - P&T Community
Posted: December 27th, 2018, 11:59am GMT
Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook P&T CommunityHOUSTON, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® ...
-
ICU Medical, Inc. to Present at the 37th J.P. Morgan Healthcare Conference - P&T Community
Posted: December 27th, 2018, 11:59am GMT
ICU Medical, Inc. to Present at the 37th J.P. Morgan Healthcare Conference P&T CommunitySAN CLEMENTE, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of ...
-
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco - P&T Community
Posted: December 27th, 2018, 10:59am GMT
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco P&T CommunityBERKELEY HEIGHTS, N.J., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the ...
-
Axsome Therapeutics Provides Year End 2018 Clinical Update - P&T Community
Posted: December 27th, 2018, 10:59am GMT
Axsome Therapeutics Provides Year End 2018 Clinical Update P&T CommunityFDA clearance of IND received for Phase 2 trial of AXS-12 in narcolepsy. Phase 2 results of AXS-05 in major depressive disorder on track for early January 2019.
-
Blood donors encouraged to keep appointments to help patients this holiday season - P&T Community
Posted: December 27th, 2018, 10:59am GMT
Blood donors encouraged to keep appointments to help patients this holiday season P&T CommunityOTTAWA, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Canadian Blood Services is asking donors to keep their appointments to give blood during the holidays to help ...
-
VIVUS to Present at Biotech Showcase on January 9, 2019 - P&T Community
Posted: December 27th, 2018, 10:59am GMT
VIVUS to Present at Biotech Showcase on January 9, 2019 P&T CommunityCAMPBELL, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the ...
-
Myriad Genetics to Present at the 37th Annual J.P. Morgan Healthcare Conference - P&T Community
Posted: December 27th, 2018, 10:59am GMT
Myriad Genetics to Present at the 37th Annual J.P. Morgan Healthcare Conference P&T CommunitySALT LAKE CITY, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that Mark C. Capone, president and CEO, ...
-
TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer | Antibodies | News Channels - PipelineReview.com
Posted: December 27th, 2018, 10:04am GMT
TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer | Antibodies | News Channels PipelineReview.comTRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of ...
-
HEXO reaches construction and licensing milestones for its massive 1 million sq. ft. greenhouse – on time and on budget - P&T Community
Posted: December 27th, 2018, 9:59am GMT
HEXO reaches construction and licensing milestones for its massive 1 million sq. ft. greenhouse – on time and on budget P&T CommunityGATINEAU, Quebec, Dec. 27, 2018 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO” or the “Company”) (TSX:HEXO) has reached a construction and licensing ...
-
TRACON Pharmaceuticals (TCON) Price Target Cut to $9.00 by Analysts at BTIG Research - PressOracle
Posted: December 27th, 2018, 9:13am GMT
TRACON Pharmaceuticals (TCON) Price Target Cut to $9.00 by Analysts at BTIG Research PressOracleTRACON Pharmaceuticals (NASDAQ:TCON) had its target price reduced by BTIG Research to $9.00 in a report published on Wednesday morning, The Fly ...
-
Organic electronics: Bio-on presents Eloxel, to develop the use of bioplastics in the electronics sector. At his side Kartell, strategic partner - P&T Community
Posted: December 27th, 2018, 7:58am GMT
Organic electronics: Bio-on presents Eloxel, to develop the use of bioplastics in the electronics sector. At his side Kartell, strategic partner P&T CommunityELOXEL is born (organic electronics for electronics) the new company created by Bio-on to exploit the patents destined to revolutionize the world of electronics ...
-
Delcath Announces Commercial Licensing Agreement for CHEMOSAT® - P&T Community
Posted: December 26th, 2018, 11:57am GMT
Delcath Announces Commercial Licensing Agreement for CHEMOSAT® P&T Community7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe. Upfront and Milestone Payments Provide Additional Resources to Advance ...
-
TRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors - P&T Community
Posted: December 26th, 2018, 11:57am GMT
TRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors P&T CommunitySAN DIEGO, Dec. 26, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the ...
-
Tracon Pharmaceuticals (TCON) PT Lowered to $9 at BTIG - StreetInsider.com
Posted: December 26th, 2018, 9:48am GMT
Tracon Pharmaceuticals (TCON) PT Lowered to $9 at BTIG StreetInsider.comBTIG analyst Robert Hazlett lowered the price target on Tracon Pharmaceuticals (NASDAQ: TCON) to $9.00 (from $13.00) while maintaining a Buy rating.
-
TRACON Pharmaceuticals Presents Positive Top-Line Clinical Data From Dose Escalation Portion Of Phase 1 Trial Of TRC105 And Opdivo For Treatment Of Non-Small Cell Lung Cancer - Clinical Leader
Posted: December 26th, 2018, 6:00am GMT
TRACON Pharmaceuticals Presents Positive Top-Line Clinical Data From Dose Escalation Portion Of Phase 1 Trial Of TRC105 And Opdivo For Treatment Of Non-Small Cell Lung Cancer Clinical LeaderTRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted.
-
Angiosarcomas Treatment Market Business Opportunties and Growth 2018 to 2026 - The Industry Chronicle
Posted: December 26th, 2018, 12:56am GMT
Angiosarcomas Treatment Market Business Opportunties and Growth 2018 to 2026 The Industry ChronicleA Research Report on Angiosarcomas Treatment Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to (2018 – 2026).
-
Angiosarcomas Treatment Market Business Opportunties and Growth 2018 to 2026 - The Industry Chronicle
Posted: December 26th, 2018, 12:56am GMT
Angiosarcomas Treatment Market Business Opportunties and Growth 2018 to 2026 The Industry ChronicleA Research Report on Angiosarcomas Treatment Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to (2018 – 2026).
-
Angiosarcomas Treatment Market To Mirror A Worldwide Expansion Throughout 2018 – 2026 - Morgan Newspaper USA
Posted: December 24th, 2018, 9:52pm GMT
Angiosarcomas Treatment Market To Mirror A Worldwide Expansion Throughout 2018 – 2026 Morgan Newspaper USAGlobal Angiosarcomas Treatment Market has potentials to grow as the most influential market worldwide as it has been playing a noteworthy role in imprinting ...
-
Insider Buying: TRACON Pharmaceuticals Inc (TCON) CEO Purchases $32,340.00 in Stock - Modern Readers
Posted: December 24th, 2018, 10:40am GMT
Insider Buying: TRACON Pharmaceuticals Inc (TCON) CEO Purchases $32,340.00 in Stock Modern ReadersTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer acquired 49000 shares of TRACON Pharmaceuticals stock in a transaction dated Friday, ...
-
ProQR Therapeutics Added to NASDAQ Biotechnology Index - P&T Community
Posted: December 24th, 2018, 6:00am GMT
ProQR Therapeutics Added to NASDAQ Biotechnology Index P&T CommunityLEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to ...
-
Microbix Enhances Quality Management System - P&T Community
Posted: December 24th, 2018, 6:00am GMT
Microbix Enhances Quality Management System P&T CommunityISO 13485:2016 Medical Devices Certification Attained. TORONTO, Dec. 24, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), ...
-
Canada House Receives Cannabis Sales License from Health Canada - P&T Community
Posted: December 24th, 2018, 6:00am GMT
Canada House Receives Cannabis Sales License from Health Canada P&T CommunityNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Dec. 24, 2018 (GLOBE NEWSWIRE) ...
-
TRACON Pharmaceuticals (TCON) Attains New 1-Year Low at $0.55 - BharataPress
Posted: December 24th, 2018, 6:00am GMT
TRACON Pharmaceuticals (TCON) Attains New 1-Year Low at $0.55 BharataPressTRACON Pharmaceuticals Inc (NASDAQ:TCON) reached a new 52-week low during trading on Friday . The company traded as low as $0.55 and last traded at ...
-
Angiosarcomas Treatment Market Revenue Growth Predicted by 2018-2026 - Coherent News
Posted: December 24th, 2018, 3:59am GMT
Angiosarcomas Treatment Market Revenue Growth Predicted by 2018-2026 Coherent NewsThe Angiosarcomas Treatment Market Report Highlights 2018 – 2026 of the market essentials, Industry review, opportunities, regional market, Emerging Growth ...
-
TRACON Pharmaceuticals Inc (TCON) CEO Charles Theuer Purchase 49000 Shares - BharataPress
Posted: December 24th, 2018, 3:20am GMT
TRACON Pharmaceuticals Inc (TCON) CEO Charles Theuer Purchase 49000 Shares BharataPressTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer purchased 49,000 shares of TRACON Pharmaceuticals stock in a transaction dated ...
-
TRACON Pharmaceuticals (TCON) Reaches New 1-Year Low at $0.55 - BharataPress
Posted: December 23rd, 2018, 6:38pm GMT
TRACON Pharmaceuticals (TCON) Reaches New 1-Year Low at $0.55 BharataPressTRACON Pharmaceuticals Inc (NASDAQ:TCON) shares hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $0.55 and last ...
-
Insider Purchaseing: TRACON Pharmaceuticals Inc (TCON) CEO Bought 49000 Shares of Shares - BharataPress
Posted: December 23rd, 2018, 4:46pm GMT
Insider Purchaseing: TRACON Pharmaceuticals Inc (TCON) CEO Bought 49000 Shares of Shares BharataPressTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer bought 49,000 shares of the stock in a transaction on Friday, December 21st. The stock ...
-
Charles Theuer Acquires 49,000 Shares of TRACON Pharmaceuticals Inc (TCON) Stock - PressOracle
Posted: December 23rd, 2018, 11:29am GMT
Charles Theuer Acquires 49,000 Shares of TRACON Pharmaceuticals Inc (TCON) Stock PressOracleTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer bought 49000 shares of the company's stock in a transaction that occurred on Friday, ...
-
National Healthcare (NYSEAMERICAN:NHC) to pay $0.50 on Mar 1, 2019; Athenex (ATNX) Shorts Lowered By 3.81% - The FinReviewer
Posted: December 23rd, 2018, 8:40am GMT
National Healthcare (NYSEAMERICAN:NHC) to pay $0.50 on Mar 1, 2019; Athenex (ATNX) Shorts Lowered By 3.81% The FinReviewerNational Healthcare Corp (NYSEAMERICAN:NHC) is expected to pay $0.50 on Mar 1, 2019. (NYSEAMERICAN:NHC) shareholders before Dec 28, 2018 will ...
-
Angiosarcomas Treatment Report Highlights The Competitive Scenario With Impact Of Drivers And Challenges 2026 - Coherent Times
Posted: December 23rd, 2018, 12:07am GMT
Angiosarcomas Treatment Report Highlights The Competitive Scenario With Impact Of Drivers And Challenges 2026 Coherent TimesThe report presents an introductory as well as detailed information about the Angiosarcomas Treatment Market through a well-organized layout divided into easy ...
-
TRACON Pharmaceuticals Inc (TCON) CEO Charles Theuer Purchases 49,000 Shares - Fairfield Current
Posted: December 22nd, 2018, 4:03pm GMT
TRACON Pharmaceuticals Inc (TCON) CEO Charles Theuer Purchases 49,000 Shares Fairfield CurrentTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer purchased 49000 shares of TRACON Pharmaceuticals stock in a transaction dated Friday ...
-
TRACON Pharmaceuticals (TCON) Reaches New 1-Year Low at $0.55 - Modern Readers
Posted: December 22nd, 2018, 10:09am GMT
TRACON Pharmaceuticals (TCON) Reaches New 1-Year Low at $0.55 Modern ReadersTRACON Pharmaceuticals Inc (NASDAQ:TCON) reached a new 52-week low during trading on Friday . The company traded as low as $0.55 and last traded at ...
-
Charles Theuer Acquires 49,000 Shares of TRACON Pharmaceuticals Inc (TCON) Stock - Baseball Daily News
Posted: December 22nd, 2018, 11:00pm GMT
Charles Theuer Acquires 49,000 Shares of TRACON Pharmaceuticals Inc (TCON) Stock Baseball Daily NewsTRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer bought 49000 shares of the business's stock in a transaction on Friday, December 21st.
-
To Help Speed Up Cancer Research, Share Your Data With Scientists - Curetoday.com
Posted: December 21st, 2018, 4:48pm GMT
To Help Speed Up Cancer Research, Share Your Data With Scientists Curetoday.comEVER WISH YOU COULD help speed the progress of cancer research? Now you can. Through a new program run by the nonprofit organization Count Me In, ...
-
TRACON Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma - P&T Community
Posted: December 21st, 2018, 11:37am GMT
TRACON Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma P&T CommunitySAN DIEGO, Dec. 21, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the ...
-
IBA to install a proton therapy solution in Charleroi, Belgium, and Dosimetry update - P&T Community
Posted: December 21st, 2018, 6:00am GMT
IBA to install a proton therapy solution in Charleroi, Belgium, and Dosimetry update P&T CommunityIBA receives purchase order to install its Proteus®ONE compact proton therapy solution in Charleroi Strategic review of Dosimetry division ongoing.
-
Supernus to Present at the 2019 J.P. Morgan Healthcare Conference - P&T Community
Posted: December 21st, 2018, 6:00am GMT
Supernus to Present at the 2019 J.P. Morgan Healthcare Conference P&T CommunityROCKVILLE, Md., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing ...
-
Aleafia-Emblem Merger Creates Canada's Largest Network of Clinics -- CFN Media - P&T Community
Posted: December 21st, 2018, 6:00am GMT
Aleafia-Emblem Merger Creates Canada's Largest Network of Clinics -- CFN Media P&T CommunitySEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network ...
-
Fortress Biotech Recaps Corporate Highlights and Achievements in 2018 - P&T Community
Posted: December 21st, 2018, 6:00am GMT
Fortress Biotech Recaps Corporate Highlights and Achievements in 2018 P&T CommunityNEW YORK, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, ...
-
EBRP, EBRF and other Global EB Charities Collaborate to Announce $1 Million Award for EB Simplex - P&T Community
Posted: December 21st, 2018, 6:00am GMT
EBRP, EBRF and other Global EB Charities Collaborate to Announce $1 Million Award for EB Simplex P&T CommunityEB Research Partnership, EB Research Foundation, the Oros Family and EB Medical Research Foundation, join together to accelerate treatments and cures for ...
-
NRC Health Trends Report Uncovers the Forces Shaping Healthcare Consumerism - P&T Community
Posted: December 21st, 2018, 6:00am GMT
NRC Health Trends Report Uncovers the Forces Shaping Healthcare Consumerism P&T CommunityReport Compiles Patient Feedback and Expert Insights; Offers Recommendations to Address 2019 Challenges. LINCOLN, Neb., Dec. 21, 2018 (GLOBE ...
-
TRACON Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma - GlobeNewswire
Posted: December 21st, 2018, 6:00am GMT
TRACON Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma GlobeNewswireSAN DIEGO, Dec. 21, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the ...